SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) 当前追踪市盈率 (P/E) 为 115.9. 追踪盈利收益率为 0.86%.
本页证实的标准:
- VALUE (15/100, 未通过) — 追踪市盈率远高于标普500平均值约25，表明估值偏高 (P/E 115.9); 追踪盈利收益率低于10年期国债收益率（约4.3%），意味着债券提供更好的回报 (EY 0.86%).
- 追踪盈利收益率 0.86% — 低于债券收益率 — 投资者为预期增长而非当前盈利支付溢价。
SharesGrow 综合评分： 45/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
15/100
Price-to-Earnings & upside
Proven by this page
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — BMYMP
估值倍数
P/E (TTM)115.9
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率16.94
EV/EBITDA0.0
每股数据
EPS (TTM)$3.45
每股账面价值$0.00
每股营收$23.61
每股自由现金流$0.00
收益率与内在价值
盈利收益率0.86%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$41.89 |
$19.43B |
$4.46B |
22.9% |
| 2017 |
$9.39 |
$20.78B |
$1.01B |
4.8% |
| 2018 |
$46.51 |
$22.56B |
$4.95B |
21.9% |
| 2019 |
$30.95 |
$26.15B |
$3.44B |
13.2% |
| 2020 |
$-84.38 |
$42.52B |
$-9B |
-21.2% |
| 2021 |
$65.61 |
$46.39B |
$6.99B |
15.1% |
| 2022 |
$45.43 |
$46.16B |
$6.33B |
13.7% |
| 2023 |
$59.44 |
$45.01B |
$8.03B |
17.8% |
| 2024 |
$-4.41 |
$48.3B |
$-8.95B |
-18.5% |
| 2025 |
$3.45 |
$48.19B |
$7.05B |
14.6% |
